61 results about "Virus receptor" patented technology

The invention provides a targeting sgRNA for pig CD163 gene editing, a modification vector, and a preparation method and application thereof, which relate to the technical field of gene engineering. The sgRNA and the gene modification vector provided by the invention have high specificity, and can be used for efficiently editing a pig CD163 gene on a cell level through a CRISPR / Cas9n system. According to the preparation method of a blue-eared disease resistant pig provided by the invention, a blue-eared disease virus receptor is damaged, the target gene CD163 is edited, no other exogenous gene is intruded, no non-specific editing is carried out on a non-CD163 gene area on a genome, a genetic background is clean and clear, and the work of later transgene safety evaluation is greatly reduced. The blue-eared disease resistant pig obtained by utilizing the invention can be ensured to survive normally, and resists the infection of a blue-eared disease virus, so that the economic loss caused by the blue-eared disease in pig husbandry is greatly reduced.

The invention discloses a novel coronavirus S protein double-region subunit nano vaccine based on pyrococcus furiosus ferritin. The virus receptor binding domain (RBD) and fusion peptide (FP) are usedtogether as a double antigen, and are connected with pyrococcus furiosus ferritin (PF_Ferritin) to from a fusion protein RBD-FP-PF_Ferritin to realize antigen multimerization; and then an eukaryoticcell expression system is used for expressing, and a 24-mer nano antigen can be formed through self-assembly of PF_Ferritin. The scheme can overcome the shortcoming of insufficient immunogenicity of RBD monomers, the obtained vaccine can significantly increase the level of a neutralizing antibody against the virus of a host, and the produced antibody has the ability to strongly block the virus from invading target cells. In addition, the vaccine of the invention is simple in preparation method, is easy to purify, and is high in safety, and the vaccine can be relatively quickly applied to clinical trials.

The invention discloses a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine. According to the Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine, a virus receptor binding domain (RBD) is used as an antigen and is connected with a helicobacter pylori polymer protein (HP _ Ferritin) to form a fusion protein RBD-HP_ Ferritin, so that antigen multimerization is realized; and expressing by using an eukaryotic cell expression system is carried out, so as to form a 24-polymer nano antigen through the self-assembly action of HP _ Ferritin. According to the scheme, the defect that RBD monomers are insufficient in immunogenicity can be overcome, the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses, and the generated antibodies have the capacity of strongly preventing the viruses from invading target cells. Moreover, the vaccine is simple in preparation method, easy to purify and high in safety, and can be quickly applied to clinical tests.

Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.

To provide peptides having high affinity for hemagglutinin and peptides having high inhibitory activity against influenza virus infection, as well as pharmaceutical compositions containing the peptides, the polypeptides having any one of SEQ ID NOs: 2 to 7, 9 to 10, and 12 to 18 are obtained by introducing mutation into a peptide having the sequence of ARLSPTMVHPNGAQP (peptide A-1: SEQ ID NO: 1) and screening for peptides having higher affinity for hemagglutinin. Further, the inhibitory activity of the peptide of SEQ ID NO: 3 against influenza virus infection can be enhanced by truncating SEQ ID NO: 3 in its C-terminus region with leaving ARLPR or ARLP. In addition, an influenza virus-infection inhibitor and an influenza preventive / therapeutic agent can be prepared by formulating these influenza virus receptor-binding peptides.

The invention relates to the field of biological medicine, and discloses a fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of the fully human monoclonal neutralizing antibody. B-type lymphocytes are screened from blood of a new coronal pneumonia rehabilitation patient, and the affinity constant of the obtained antibody and a virus receptor binding domain (RBD) is 1.19 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound, it is found that the binding epitope of the antibody and the binding epitope of a host cell receptor (ACE2) are highly overlapped, binding of the RBD and the ACE2 can be competitively blocked, and infection of the RBD and the ACE2 is inhibited. The antibody can cope with certain genetic mutations of viruses, the half effective concentration of the antibody for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.57 ng / mL, and the antibody has the advantages of safety, high efficiency and broad spectrum, and is expected to be used as a neutralizing antibody drug for diagnosing, treating and preventing new coronal pneumonia.

The invention discloses a cell line for stable expression of a peste des petits ruminants virus receptor Nectin-4 and a construction method of the cell line. According to the invention, by virtue of asynthetic Nectin-4 gene and on the basis of a lentiviral vector system, a recombinant plasmid pLOV-eGFP-Nectin-4 is constructed. The recombinant plasmid, together with pSPAX2 and pMD2.G plasmid, is applied to co-transfection of a 293T cell, so that retrovirus-like particles are obtained. A supernatant-infected MDBK cell is cultivated by virtue of cells containing the retrovirus-like particles, and puromycin screening and purifying are conducted, so that the MDBK cell for stable expression of Nectin-4 protein is obtained, and the MDBK cell is named as MDBK-Nectin-4. Through the construction ofthe cell line, an experimental material is provided for deep research of an interaction between PPRV and the receptor Nectin-4 and for the clinical rapid isolation of the PPRV is provided.

The invention relates to a zinc gluconate sugar tablet preparation and a preparation method thereof. The sugar tablet comprises the following components by mass: 93.24-160 parts of zinc gluconate and pharmaceutic excipients such as 1460-2500 parts of white sugar, 2910-5000 parts of maltose syrup or glucose syrup, 30-52 parts of glycine, 438-750 parts of purified water and 30-52 parts of fruit flavoring agents. The preparation is prepared by dissolving sugar at high temperature, boiling sugar under vacuum, etc. The form of the preparation is semi-transparent hard sugar tablet and the preparation is the buccal tablet. The sugar tablet is dissolved in the mouth, so that the zinc ions can permeate the nose, throat and susceptible tissues in the nasal sinus to be combined with the influenza virus receptor to prevent the influenza virus from further spreading among the cells so as to achieve the aims of treating cold and alleviating cold symptoms.

The invention discloses a recombinant A subgroup avian leukosis virus being able to express an ALV-J envelope protein, and a construction method and a use of the virus. The virus adopts ALV-A infectious clone as a skeleton, the envelope protein of the ALV-A infectious clone is replaced by the ALV-J envelope protein, and the 3' end of the envelope protein carries luciferrase report gene, so the infectious clone of the recombinant ALV-A virus being able to express the ALV-J envelope protein is constructed. Experiments prove that the recombinant virus obtained through infectious clone rescuing has high replication ability, the tilter of the virus reaches 10<5.21> TCID50 / ml, and is 125 times that of an ALV-J original strain, and the luciferrase report gene is carried out in order to realize easy quantification. The recombinant virus can infect 293T cells for expressing chNHE1, and can be detected 8h after infection at the earliest, so the recombinant virus has high sensitivity. The a recombinant A subgroup avian leukosis virus solves the problems of low virus titer, low replication ability, and adverseness of a small amount of the virus in the early stage of virus infection to detection of traditional ALV-J viruses, and is of great significance to carry out researches related with viruses and virus receptors and anti-ALV-J antibody detection.

The present invention provides a modified paramyxovirus containing a reduced amount of receptor-binding protein compared with the wild type; a method of preparing a modified paramyxovirus, comprising the following steps: (1) a step for introducing a nucleic acid that suppresses the expression of a receptor-binding protein of a paramyxovirus into an animal cell, (2) a step for infecting the paramyxovirus to the cell, and (3) a step for isolating paramyxovirus particles replicated in the cell; and a modified paramyxovirus prepared by the method of preparation mentioned above.The present invention also provides a chimera protein wherein a fusion protein of a virus has been joined or bound to a peptide that binds specifically to a cell surface marker; a nucleic acid that encodes the chimera protein; an animal cell capable of expressing the chimera protein on the cell surface thereof; a modified paramyxovirus expressing the chimera protein on the virus particle surface thereof; and a method of preparing a tissue targeting paramyxovirus, comprising: (1) a step for supplying a nucleic acid that encodes a chimera protein wherein a fusion protein of a virus has been joined or bound to a peptide that binds specifically to a cell surface marker of the target cells, (2) a step for introducing the nucleic acid supplied in (1) into an animal cell in an expressible state, and expressing the same, (3) a step for infecting a paramyxovirus to the cell, and (4) a step for isolating paramyxovirus particles replicated in the cell.

Disclosed is a method for screening acceptor blocker for controlling prawn virus infection, wherein the combined analytic technique for virus and prawn cell membrane protein is employed for the screening process of the virus receptor bonding blocking agent, and screening is achieved by comparing the influence of the screening article treatment to the combination of virus and prawn cell membrane protein, the three screened substances have blocking-up action to the combination of leukoplakia syndrome virus and prawn branchia cell membrane.

A monoclonal antibody B for the white spot virus receptor of prawn is prepared from the hybrid tumor cell (CCTCC-C200418) through conventional culture for 2-3 days to secrete a lot of said monoclonal antibody B. It can be used for preventing and treating whit spot of prawn.

The invention provides a novel coronapneumonia virus receptor ACE2 affinity adsorbent as well as a preparation method and application thereof. The novel coronapneumonia virus receptor ACE2 affinity adsorbent comprises a carrier microsphere and a novel coronapneumonia virus receptor ACE2 aptamer combined on the surface of the carrier microsphere. The surface of the carrier microsphere is modified by amino, the surface of the novel coronapneumonia virus receptor ACE2 aptamer is modified by carboxyl, and the amino on the surface of the carrier microsphere and the carboxyl on the surface of the novel coronapneumonia virus receptor ACE2 aptamer form a stable amido bond. The virus adsorbent has the advantages of simple structure, easily available raw materials, high coupling efficiency and stability, simple and controllable preparation method, one-step synthesis, high yield and good development prospect. The aptamer can be recycled after being recovered and enriched, so that the cost is greatly reduced. The novel coronavirus receptor ACE2 virus adsorbent has a huge application prospect in the field of novel coronavirus immune adsorption.

The invention discloses a portunus trituberculatus reovirus receptor, a screening method and application thereof. The portunus trituberculatus reovirus receptor is characterized by being microtubulin. The screening method comprises the following steps: anatomizing healthy trituberculatus on ice, taking branchiae and adding the branchiae to a membrane protein extracting liquid, homogenizing, and performing resuspension on sediments obtained through centrifugation by the membrane protein extracting liquid so as to obtain a branchia membrane protein extracting liquid of portunus trituberculatus; performing separation on the membrane protein by using 8% SDS-PAGE and electrotransferring the membrane protein to a PVDF (polyvinylidene fluoride) membrane, performing overnight incubation by low-fat milk under 4 DEG C, washing the incubated membrane for three times, incubating the washed membrane for an hour by SCRV virus under room temperature, washing the incubated membrane for three times again, incubating the washed membrane by chicken antibody SCRV under room temperature for two hours, washing the incubated membrane for three times, incubating the washed membrane by a goat-anti-chicken second antibody in HRP coupling under room temperature for an hour, washing the incubated membrane for four times, performing color development by OPD so as to obtain a protein band, namely the SCRV receptor. The portunus trituberculatus reovirus receptor has the advantages that a receptor blocking agent has inhibitory activity to SCRV infection cells, and a medicine for preventing and treating SCRV infection can be developed.

The invention discloses an optimized target object capturing system based on a bacterial cell surface display system, namely, the optimized target object capturing system comprises the following steps: inserting a segment of coding genes of adaptor protein between a virus capsid protein coding gene and a coding gene inaQn which is responsible for transmembrane, transfer and anchoring and is in an N-terminal structure domain of ice-nucleation protein, and establishing recombinant plasmid of inducible surface display virus capsid protein after verifying; transforming host bacteria, thus obtaining an updated bacterial cell surface display system of capsid protein; displaying virus capsid protein on the surface of escherichia coli cells through inducible expression, thus obtaining an optimized virus receptor capturing system. Compared with a traditional virus receptor purification and analysis method, the bacterial cell surface display system has the advantages that the cost of a reagent is low, the operation is simple, the experimental period is short, requirements on experimental equipment are low, a virus receptor can be easily separated, background interference is reduced, and the like; an updated virus receptor capturing system lays a solid foundation for efficiently discovering new virus receptors, and meanwhile, a new thought for protein purification and concentration is also provided.

The invention mainly relates to an affinity peptide capable of being combined with hog cholera virus E2 protein and application of the affinity peptide. The sequence of the affinity peptide is HRKWKSKWK(P7). The affinity peptide has the advantages that a bovine viral diarrhea virus E2 protein crystal structure is used as the template, homologous modeling is performed to obtain the three-dimensional structure of hog cholera virus E2 protein, the peptide sequence with high score is obtained by the aid of the virtual molecular docking technology, and the obtained peptide sequence is P7; ELISA andSPR tests are used to identify the interaction affinity and specificity between the artificially-synthesized P7 sequence and the E2 protein, and the result shows that the P7 and the E2 can be combined in a high affinity and specificity manner; the qRT-PCR and IPMA tests are used to verify the virus infection inhibiting activity of the P7 sequence, and the result shows that the P7 sequence has good activity in hog cholera virus infection PK-15 cell inhibition; the affinity peptide can provide a reliable theoretical basis and new thought for the further research of virus receptor and antiviraldrug design.

This invention relates to a new cell receptor of the PRRS virus, i.e. as non-muscle myosin II-A (NMHC II-A)and its inhibitor blebbistatin, which can be used as a drug for suppressing PRRS virus infection of cells. The invention provides a method of utilizing purified NMHC II-A protein, artificially synthesized polypeptides and blebbistatin to prevent PRRS viruses from infecting cells. It also offers the antibodies generated by NMHC II-A protein and polypeptides. The purified NMHC II-A protein or artificially synthesized polypeptides and blebbistatin as well as anti-NMHC II-A protein and anti-polypeptide antibodies all have inhibitory effects on cell infection from the PRRS virus, and can be developed into drugs for preventing and treating infections of the PRRS virus.

The invention discloses a series of affinity polypeptides YQC-1 and YQC-2 related to a coxsackie adenovirus receptor. The polypeptides possibly realize near-infrared imaging of specific malignant tumors due to the property of specific binding of the coxsackie adenovirus receptor, can be used for preparation of drugs for cell adhesion inhibition, diagnosis or tracing of tumors and targeted chemotherapy and used for pharmaceutical necessities or attachments, so that the aim of nondestructively monitoring early malignant tumors in situ in real time is achieved. The invention relates to the field of drugs related to tumor diagnosis, and in particular to multiple polypeptides, affinity tests of the polypeptides, pharmaceutical compositions taking the polypeptides as active ingredients, and application of the polypeptides in preparation of diagnostic drugs.

The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.

The present invention relates to the linear ligand epitope of Bursal bursal virus and its specific application. The polypeptide P22 on the IBDVVP2 protein is synthesized, and the CEF is used as the target cell. Through the infection and harvest of IBDV, the virulence and half tissue culture of IBDV are measured. Infection dose and infection ratio, the combination test of synthetic polypeptides and target cells, the virus blocking test and the test of polypeptide blocking IBDV infection target cells, the screened specific binding target cells can inhibit virus infection ligand epitope polypeptides, and The ligand epitope of IBDV was precisely mapped. The polypeptide P22 of the present invention can inhibit IBDV from infecting CEF, and with the increase of polypeptide concentration, the infection rate of CEF decreases in a dose-dependent manner. When the polypeptide concentration is 0.2 mmol / L, it can completely inhibit IBDV from infecting CEF target cells. The invention provides a theoretical basis for further research on the virus ligand epitope from the aspect of the interaction between the virus ligand and the virus receptor.

The present invention provides a method for improving the gene therapy efficiency by overexpressing adeno-associated virus receptors, and particularly provides an infection enhancing element having the following structure: Z1-Z2-Z3-Z4(I); Z1 is an optional signal peptide element; Z2 is a PKD-1 structural domain, a PKD-2 structural domain or a PKD-1-PKD-2 structural domain; Z3 is a no or PKD-3 structural domain; Z4 is a transmembrane element; '-' means a peptide bond connecting the above elements; with the additional condition that when Z3 is a PKD-3 element, Z4 is not a transmembrane element of an AAVR (Adeno-Associated Virus Receptor). The infection enhancing element provided by the invention can significantly improve the infection efficiency of an AAV virus vector system and also improvethe gene editing efficiency, and can significantly reduce the blood phenylalanine content of a phenylketonuria-treated mouse, thereby treating the phenylketonuria.

The invention belongs to the field of Western medicines and discloses an application of oxetanocin in preparation of an antiviral medicament. The application of oxetanocin and derivatives thereof in preparation of antiviral medicaments is preferably used for preparing medicaments for resisting HIV (Human Immunodeficiency Virus) and / or influenza viruses. An antivirus mechanism of oxetanocin is directly related with entrance of the viruses in cells. By analysis on time dynamic expression of oxetanocin, the most possible mechanism of oxetanocin changes flowing of a cell membrane virus receptor. When being put into a cell culture dish before virus infection, the oxetanocin is adsorbed on a cell membrane to restrain the viruses on the cell membrane so that the receptor on the surface of the cell is not easy to have contact with infection protein of the virus, or the oxetanocin has reaction with the receptor on the surface of the cell so that the receptor is not easy to have contact with other proteins.

The invention provides a fusion protein and application thereof. The fusion protein comprises nuclease, a virus antibody or a virus receptor. The fusion protein for preventing and treating viral infectious diseases is faster and easier to develop than vaccines, and has higher safety and effectiveness. The fusion protein can be popularized and applied to prevention and treatment of various virus infectious diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to a virus receptor protein for diagnosing leucoderma and application thereof. The invention discloses application of a molecular marker in preparation of a diagnostic kit for diagnosing leucoderma. The molecular marker is human skin melanocyte HSV-1 receptor protein. The human skin melanocyte HSV-1 receptor protein is determined by using a western blot method to carry out semi-quantitative analysis and predict whether the protein level is reduced or not. Experiments prove that after HSV-1 infects human melanocytes, expression of melanin synthesis related protein and a melanin synthesis function are inhibited by up-regulating VN1R5, so that leucoderma is caused. The process of the human skin melanocyte HSV-1 receptor protein is not complex, the detection result can be obtained by using a microplate reader, and the kit is mature in manufacturing means, easy to purchase and capable of being popularized in clinical application. It is found in the early stage that the reduced human skin melanocyte HSV-1 receptor protein level is beneficial to diagnosis of leucoderma, guidance of next treatment is facilitated, and the risk of disease deterioration of leucoderma patients is reduced.